research Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α-Reductase Inhibitor
New hybrid compound found to effectively prevent hair loss.
Search
forLearn
0 / 0 results — no results
Research
5 / 57 results 
research Therapeutic Control of Androgen Action
Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.
Community Join
3 / 3 resultscommunity We need actual hair loss studies on Epristeride
Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community New Hair Loss Treatment from Kintor Just Hit the Market: KX-826!
Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.